Latest / The BioHub - by Avetix
Episode 100 - Lance Baldo - CEO of Beacon Therapeutics
We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference.
Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026.
Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon.
We also cover Lance's experience as a first-time CEO, and his advice for other executives making that…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.